{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT02493868_SUSTAIN1\\NCT02493868_SUSTAIN1_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "All Enrolled Analysis Set",
        "text": "The all enrolled analysis set includes all subjects who signed an informed consent form and were assigned a subject number.",
        "populationType": "Other",
        "instanceType": "AnalysisPopulation",
        "label": "All Enrolled",
        "populationDescription": "The all enrolled analysis set includes all subjects who signed an informed consent form and were assigned a subject number.",
        "criteria": "Signed informed consent AND assigned a subject number"
      },
      {
        "id": "pop_2",
        "name": "Full Analysis Set",
        "text": "The full analysis sets (one for stable remitters and one for stable responders) include all randomized subjects who received at least one dose of intranasal study medication or one dose of oral antidepressant during the maintenance phase. Transferred-entry subjects who continue to receive an oral antidepressant plus intranasal placebo will not be included in the full analysis sets.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "The full analysis sets (one for stable remitters and one for stable responders) include all randomized subjects who received at least one dose of intranasal study medication or one dose of oral antidepressant during the maintenance phase. Transferred-entry subjects who continue to receive an oral antidepressant plus intranasal placebo will not be included in the full analysis sets.",
        "criteria": "Randomized AND (received >=1 dose of intranasal study medication OR >=1 dose of oral AD during maintenance phase) AND NOT (transferred-entry subject on oral AD plus intranasal placebo)"
      },
      {
        "id": "pop_3",
        "name": "Interim Full Analysis Set",
        "text": "The interim full analysis set includes all randomized subjects in the stable remitter set who have either relapsed or have been followed for at least 12 weeks in the maintenance phase at the time of the interim analysis data cut-off.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Interim FAS",
        "populationDescription": "The interim full analysis set includes all randomized subjects in the stable remitter set who have either relapsed or have been followed for at least 12 weeks in the maintenance phase at the time of the interim analysis data cut-off.",
        "criteria": "Randomized AND stable remitter AND (relapsed OR followed for >=12 weeks in maintenance phase at data cut-off)"
      },
      {
        "id": "pop_4",
        "name": "Safety Analysis Set",
        "text": "The safety analysis sets (one for each phase) include all subjects who received at least one dose of intranasal study medication or one dose of oral antidepressant in that phase.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The safety analysis sets (one for each phase) include all subjects who received at least one dose of intranasal study medication or one dose of oral antidepressant in that phase.",
        "criteria": "Received >=1 dose of intranasal study medication OR >=1 dose of oral AD in the specific phase"
      },
      {
        "id": "pop_5",
        "name": "Follow-up Analysis Set",
        "text": "The follow-up analysis set includes all subjects who entered the follow-up phase.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "FU",
        "populationDescription": "The follow-up analysis set includes all subjects who entered the follow-up phase.",
        "criteria": "Entered the follow-up phase"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Demographics",
        "code": "DEMOGRAPHICS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Demographics",
        "dataType": "Mixed",
        "instanceType": "Characteristic",
        "description": "Age, sex, race, and ethnicity"
      },
      {
        "id": "char_2",
        "name": "Baseline Characteristics",
        "code": "BASELINE_CHARACTERIS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Baseline Characteristics",
        "dataType": "Mixed",
        "instanceType": "Characteristic",
        "description": "Baseline MADRS total score, BMI, and psychiatric history"
      }
    ],
    "summary": {
      "populationCount": 5,
      "characteristicCount": 2
    }
  }
}